CA2559685A1 - Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423) - Google Patents

Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423) Download PDF

Info

Publication number
CA2559685A1
CA2559685A1 CA002559685A CA2559685A CA2559685A1 CA 2559685 A1 CA2559685 A1 CA 2559685A1 CA 002559685 A CA002559685 A CA 002559685A CA 2559685 A CA2559685 A CA 2559685A CA 2559685 A1 CA2559685 A1 CA 2559685A1
Authority
CA
Canada
Prior art keywords
dosage form
pharmaceutical dosage
form according
active substance
coat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002559685A
Other languages
English (en)
French (fr)
Inventor
Marija Bogataj
Ales Mrhar
Anton Lavric
Manica Cerne
Doris Tibaut
Anton Stalc
Uros Urleb
Tatjana Mateovic
Greta Cof
Janez Kerc
Rok Dreu
Fumio Yoneda
Shizuko Muraoka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lek Pharmaceuticals dd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2559685A1 publication Critical patent/CA2559685A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002559685A 2004-03-26 2005-03-24 Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423) Abandoned CA2559685A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SIP200400094 2004-03-26
SI200400094 2004-03-26
PCT/EP2005/003175 WO2005092295A1 (en) 2004-03-26 2005-03-24 Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)

Publications (1)

Publication Number Publication Date
CA2559685A1 true CA2559685A1 (en) 2005-10-06

Family

ID=34964906

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002559685A Abandoned CA2559685A1 (en) 2004-03-26 2005-03-24 Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)

Country Status (15)

Country Link
US (1) US20100183714A1 (https=)
EP (1) EP1734933B1 (https=)
JP (1) JP2007530492A (https=)
CN (1) CN1956707B (https=)
AR (1) AR048342A1 (https=)
AT (1) ATE468846T1 (https=)
AU (1) AU2005226927B2 (https=)
BR (1) BRPI0509271A (https=)
CA (1) CA2559685A1 (https=)
DE (1) DE602005021475D1 (https=)
MY (1) MY145329A (https=)
PE (1) PE20051163A1 (https=)
RU (1) RU2375047C2 (https=)
TW (1) TW200600121A (https=)
WO (1) WO2005092295A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273376B2 (en) 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
CN101795675A (zh) * 2006-11-17 2010-08-04 达沃尔泰拉公司 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送
WO2009037264A2 (en) * 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
ES2627745T3 (es) * 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
EP3915552A1 (en) * 2015-06-01 2021-12-01 Xeno Biosciences Inc. Compositions for use in modulating the gut microbiota and managing weight
BR112018077032A2 (pt) * 2016-06-23 2019-04-02 Nutrivert Llc método para aprimorar o crescimento ou a conversão alimentar em um animal, uso de pgn, mdp ou um análogo de mdp na preparação de um medicamento e pgn, mdp ou um análogo de mdp
WO2018085935A1 (en) * 2016-11-09 2018-05-17 Engene, Inc. Intestinal expression of programmed death ligand 1
BR112019012071A2 (pt) * 2016-12-14 2019-11-12 Progenity Inc tratamento de uma doença do trato gastrointestinal com um inibidor de integrina
EP3554485B9 (en) * 2016-12-14 2023-09-27 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
EP3554342B1 (en) * 2016-12-14 2024-07-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
CN108968074B (zh) * 2018-06-06 2021-09-28 福建省农业科学院农业工程技术研究所 一种结肠靶向递送的银耳糖醛酸多糖-芙蓉李花青素复合物及其制备方法
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
ES3014076T3 (en) 2020-03-26 2025-04-16 Nutrivert Inc Lipophilic enantiomers of desacetylglucosamine muramyl dipeptide with anti-inflammatory and growth promoting activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2113221C1 (ru) * 1990-05-04 1998-06-20 Ииссум Рисерч Дивелопмент Компани оф дзе Хебрю Юниверсити оф Иеруcалим Фармацевтическая форма для введения лекарственного средства в ободочную кишку, способ введения лекарственного препарата и способ получения матриц для такой формы
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
YU183090A (sh) * 1990-09-27 1992-12-21 Lek Novi n-acildipeptidi, postopki za njihovo pripravo in farmacevtski pripravki, kojih vsebujejo
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems

Also Published As

Publication number Publication date
ATE468846T1 (de) 2010-06-15
PE20051163A1 (es) 2006-02-21
EP1734933A1 (en) 2006-12-27
US20100183714A1 (en) 2010-07-22
RU2006137660A (ru) 2008-05-10
EP1734933B1 (en) 2010-05-26
AU2005226927A1 (en) 2005-10-06
CN1956707A (zh) 2007-05-02
JP2007530492A (ja) 2007-11-01
BRPI0509271A (pt) 2007-09-04
AR048342A1 (es) 2006-04-19
MY145329A (en) 2012-01-31
RU2375047C2 (ru) 2009-12-10
DE602005021475D1 (de) 2010-07-08
AU2005226927B2 (en) 2010-09-23
CN1956707B (zh) 2010-12-29
WO2005092295A1 (en) 2005-10-06
TW200600121A (en) 2006-01-01

Similar Documents

Publication Publication Date Title
ES2568746T3 (es) Sistemas de liberación pulsátil controlada
KR100280099B1 (ko) 방출 개시 제어 및 방출 속도 제어형 제제
EP0391518B1 (en) Sustained-release pharmaceutical preparation
JP4436475B2 (ja) 固体の経口用薬剤形のための結合剤または被覆の製造に適当な水性分散液、該水性分散液の使用および再分散性粉末
FI105255B (fi) Menetelmä viivästyneesti vapauttavan, suun kautta annettavan annostelumuodon valmistamiseksi
USRE42096E1 (en) Oral pulsed dose drug delivery system
CA2297832C (en) Pellet-type formulation intended for treating the intestinal tract
JP2007532689A (ja) 医薬有効成分の遅延性かつ調節性放出のための微粒子経口ガレヌス製剤
EP1734933B1 (en) Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)
Saigal et al. Site specific chronotherapeutic drug delivery systems: A patent review
KR20080028361A (ko) 퀴닌-함유 제어-방출형 제제
EP2533766A2 (en) Pharmaceutical mini-tablets for sustained release of flecainide acetate
JP2004505034A (ja) 制御された放出のシグモイドパターンを示すエレトリプタンの粒状組成物
WO2004024128A2 (en) Modified release ketoprofen dosage form
CA2647765A1 (en) Coated formulations
AU2005261958A1 (en) Granules for controlled release of Tamsulosin
WO2009065130A2 (en) Modified release formulations of diltiazem
EP0956006A1 (en) Colonic delivery of weak acid drugs
WO2008079102A1 (en) Modified release loxoprofen compositions
US20030044465A1 (en) Sustained release oral preparations
WO2010036975A2 (en) Dipyridamole and acetylsalicylic acid formulations and process for preparing same
ME00452B (me) Mikrokapsule za odloženo i kontrolisano oslobadjanje perindoprila
KR100858631B1 (ko) 인다파미드가 함유된 서방형 펠렛
KR100501827B1 (ko) 다층 코팅법을 이용한 멜라토닌 함유 타게팅 약물 전달 기구
CA3098604A1 (en) Dosage forms for delivery of medicines to the lower gastrointestinal tract

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued